<DOC>
	<DOCNO>NCT00467961</DOCNO>
	<brief_summary>This study try improve safety effectiveness stem cell transplant procedures patient cancer blood . It use special machine separate immune cell ( T cell ) blood donor patient use photodepletion , laboratory procedure selectively kill cancer cell expose light . These special procedure may reduce risk graft-versus-host-disease ( GVHD ) , serious complication stem cell transplant donor 's immune cell destroy patient 's healthy tissue , time may permit great graft-versus-leukemia effect , donate cell fight residual tumor cell might remain body . Patients 18 75 year age life-threatening disease bone marrow ( acute chronic leukemia , myelodysplastic syndrome , myeloproliferative syndrome ) may eligible study . Candidates must family member suitable tissue match .</brief_summary>
	<brief_title>Stem Cell Transplantation Patients With Cancers Blood</brief_title>
	<detailed_description>Peripheral blood stem cell transplant research carry NHLBI BMT Unit focus approach transplant technique design decrease graft versus host disease ( GVHD ) , increase graft-versus-leukemia ( GVL ) effect , and/or reduce risk post-transplant graft rejection disease relapse . Ex vivo selective depletion alloreacting T cell , hereafter refer selective depletion ( SD ) , represent translational strategy aim reduce severe GVHD whilst preserve GVL . We find selectively depleted transplant safe administer associate less severe acute GVHD . This protocol design evaluate safety efficacy photodepletion ( PD ) improve selective depletion procedure HLA-matched peripheral blood stem cell transplant set determine whether post-transplant immunosuppression cyclosporine necessary prevent severe GVHD photodepleted transplant . The protocol accrue subject age 18-75 diagnosed hematological malignancy allogeneic stem cell transplantation HLA-matched sibling would normally indicate . Diagnostic category include acute chronic leukemia , myelodysplastic syndrome , B-cell lymphoma , multiple myeloma , myeloproliferative syndrome . Participants central intravenous ( IV ) line place large vein . The tube use give donated stem cell antibiotic medicine , transfusion red blood cell platelet , collect blood sample . Treatment start condition regimen chemotherapy ( fludarabine cyclophosphamide ) total body irradiation suppress immunity prevent rejection donate stem cell . The day chemotherapy end , stem cell give central line . This follow transfusion donor 's immune cell , treat remove cell could cause severe GVHD . Also minimize risk GVHD , patient give cyclosporine . Not participant receive amount drug ; order determine much immunosuppression need protect severe GVHD , length treatment cyclosporine varies among patient , depend enter study well precede patient . The average hospital stay stem cell transplantation 3 4 week . Patients return frequent follow-up visit first 2 4 month transplantation . The patient 's refer physician ask send result laboratory test NIH researcher least every 3 month first 3 year annually thereafter . Patient follow-up visit schedule NIH 1 , 2 , 3 year transplantation . After 3 year , participant offer opportunity enroll NHLBI 's long-term evaluation follow-up care protocol . Subjects receive myeloablative conditioning regimen cyclophosphamide , fludarabine total body irradiation , follow infusion stem cell product prepare use Miltenyi CliniMacs system CD34 selection lymphocyte product selectively deplete use photodepletion approach ( Kiadis Pharma ) . Older subject receive low dose irradiation reduce regimen intensity . To determine appropriate level post transplant immunosuppression , utilize three sequential de-escalation stage design involve 17 subject per cohort ( minimum 17 , maximum 51 total evaluable subject study ) . Stopping rule non-relapse mortality cohort determine whether continue next stage ; continue accumulate subject level ; stop protocol . Cohort 1 : Low dose cyclosporine day 90 dose taper stop within 2 week . Cohort 2 : If severe GVHD encounter Cohort 1 , cyclosporine withdrawal begin day 45 . Cohort 3 : If severe GVHD encounter Cohort 2 , cyclosporine use post-transplant period . Primary endpoint incidence acute grade III/IV GVHD day 90 . Secondary endpoint standard transplant outcome variable : toxicity , non relapse mortality survival .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<criteria>INCLUSION CRITERIA : Recipient Criteria : Diagnosed one follow hematological condition : Chronic myelogenous leukemia ( CML ) : chronic phase fail treatment imatinib , intolerance imatinib , receive imatinib therapeutic dos within first 12 month diagnosis ; accelerate phase blast transformation . Acute Blymphoblastic leukemia ( BALL ) : category : BALL first remission highrisk feature ( present leukocyte count great 100,000/cu mm , Karyotypes t9 ; 22 , t4 , t19 , t11 , biphenotypic leukemia ) , second subsequent remission , primary induction failure , partially respond untreated relapse . Acute myelogenous leukemia ( AML ) : AML first remission except AML good risk karyotype : AML M3 ( t15 ; 17 ) , AML M4Eo ( inv 16 ) , AML ( 8 ; 21 ) . All AML second subsequent remission , primary induction failure resistant relapse . Myelodysplastic syndrome ( MDS ) : category refractory anemia transfusion dependence , refractory anemia excess blast , transformation acute leukemia , chronic myelomonocytic leukemia , atypical MDS/myeloproliferative syndrome . Myeloproliferative disorder include atypical ( Ph negative ) chronic myeloid neutrophilic leukemia , progress myelofibrosis , polycythemia vera , essential thrombocythemia transformation acute leukemia progressive transfusion requirement pancytopenia . Chronic lymphocytic leukemia refractory fludarabine treatment bulky progressive disease thrombocytopenia ( less equal 100,000 /microl ) anemia ( less equal 10g/dl ) due recent chemotherapy . NonHodgkin 's lymphoma include Mantle cell lymphoma relapse refractory standard care treatment . Multiple myeloma , Waldenstroms macroglobulinemia , unresponsive relapse follow standard care treatment . Ages 1875 year inclusive . HLA identical ( 6/6 ) relate donor . Ability comprehend investigational nature study provide inform consent . Donor Criteria : Related HLA identical ( 6/6 ) recipient . Weight great equal 18 kg . Age great equal 2 less equal 80 year old . For adult : Ability comprehend investigational nature study provide inform consent . For minor : Written inform consent one parent guardian inform assent : The process explain minor level complexity appropriate age ability comprehend . EXCLUSION CRITERIA : Recipient Criteria ( follow ) : Malignant cell express T cell phenotype ( particular TALL T cell NHL ) . DLCO le 65 percent predict . Left ventricular ejection fraction le 40 percent ( evaluated ECHO ) less 30 percent ( evaluated MUGA ) . AST/SGOT great 10 time ULN ( CTCAE grade IV v3.0 ) . Bilirubin great 5 time ULN ( CTCAE grade IV v3.0 ) . Creatinine great 4.5 time ULN ( CTCAE grade IV v 3.0 ) . HIV positive ( Recipients positive hepatitis B ( HBV ) , hepatitis C ( HCV ) human Tcell lymphotropic virus ( HTLV1/II ) exclude participation ) . Positive pregnancy test woman childbearing age . Prior allogeneic stem cell transplantation . Estimated probability survive less three month . Major anticipated illness organ failure incompatible survival transplant . Severe psychiatric illness mental deficiency sufficiently severe make compliance transplant treatment unlikely informed consent impossible . Donor Criteria ( follow ) : Pregnant lactating . Unfit receive filgrastim ( GCSF ) undergo apheresis ( abnormal blood count , history stroke , uncontrolled hypertension ) . Sickling hemoglobinopathy include HbSS , HbAS , HbSC . HIV positive Donors positive hepatitis B ( HBV ) , hepatitis C ( HCV ) human Tcell lymphotropic virus ( HTLVI/II ) use discretion investigator follow counsel approval recipient . Severe psychiatric illness mental deficiency sufficiently severe make compliance donation stem cell unlikely informed consent impossible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>CML ( Chronic Myelogenous Leukemia )</keyword>
	<keyword>CLL ( Chronic Lymphocytic Leukemia )</keyword>
	<keyword>AML ( Acute Myelogenous Leukemia )</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>CLL</keyword>
	<keyword>Chronic Myelogenous Leukemia</keyword>
	<keyword>CML</keyword>
	<keyword>Acute Myelogenous Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Acute B-Lymphoblastic Leukemia</keyword>
	<keyword>ALL</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>MDS</keyword>
</DOC>